"Enabling Genomics in Routine Medical Care"
Radiation Exposure
DxTerity Diagnostics has developed an innovative molecular test for acute radiation exposure – the REDI-Dx™ RUO* test. Using the DxTerity DxDirect™ method for direct-from-sample, multiplex gene-expression analysis and a proprietary panel of radiation-sensitive biomarkers, REDI-Dx™ is a simple, rapid, highly specific, and low-cost solution for biodosimetry and emergency management research that is superior to existing methods for estimating radiation exposure.
(*For Research Use Only)
- Features
- Specs
- Data
- Documents
- Simple workflow and procedure.
- Rapid throughput and time to results
- Direct analysis from buffer-stabilized whole blood
- One step blood collection and ambient sample transport using DxCollect™
- Readily adapts to industry-standard capillary electrophoresis systems – such as the family of Applied Biosystem (ABI) Genetic Analyzers
- Software analysis automation tool saves time and ensures standardized results
|
Analytical Range: |
0-10 Gy *Research Use Only |
|
Reagent |
 |
REDI-Dx RUO Clinical Brief Overview of use model of test in emergency response research read more... |
|
Chemistry White Paper (DxDirect) Data and Background on DxDirect and NEAT™ read more... |
|
REDI-Dx RUO Product Flyer |
||
|
REDI-Dx RUO White Paper Scientific Background and Data read more... |
Recent News
DxTerity Launches REDI-Dx RUO for Acute Radiation Exposure read more...
DxTerity and Duke win $43M Radiation Biodosimetry Contract for National Emergency Response Program. read more...